Inactive Instrument

Highlights Discovery Laboratories, Inc. Nasdaq

Equities

US2546684034

End-of-day quote Nasdaq Other stock markets
- ^USD	-

04-16	Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-11	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Reverse Split: 1 of 18	04-21	FA
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
North American Morning Briefing : Stock Futures -2-	04-11	DJ
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	04-09	MT
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	04-07	CI
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	02-01	CI
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	01-17	CI
Windtree Therapeutics, Inc. Announces Reduction in Arrythmias in a New Study With Istaroxime And A Pure SERCA2a Activator	01-02	CI
Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	12-18	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Windtree Therapeutics Secures US Patent Covering Product Candidates Aimed to Treat Heart Failure Patients	23-08-23	MT
Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators	23-08-16	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Windtree Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement	23-03-13	MT
Windtree Therapeutics, Inc. Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure	23-02-28	CI
Windtree Therapeutics Secures New Patent for Experimental Heart Failure Drug Candidate	23-02-24	MT
Reverse Split: 1 of 50	23-02-23	FA
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Discovery Laboratories, Inc. Nasdaq

Equities

US2546684034

Highlights

Filters